Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections

The Centers for Disease Control and Prevention (CDC) characterized carbapenem-resistant Enterobacteriaceae (CRE) as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”.

Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE.

Achaogen is developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens.

The Challenge: According to the Centers for Disease Control and Prevention, at least 2 million people become infected with bacteria that are resistant to antibiotics each year in the United States. They believe that new antibacterials for gram-negative bacterial infections are desperately needed.

The People: They have deep expertise in the discovery, development and commercialization of new antibacterial drugs, including a fundamental expertise in the relationship between chemical structure and gram-negative potency. In addition, the interdisciplinary teams made up of seasoned professionals enable us to design and conduct large, global clinical trials.

The Approach: They are committed to identifying and developing product candidates to treat multi-drug resistant (MDR) gram-negative infections. They have in-depth knowledge about the relationship between compound structure and potency against gram-negative bacteria through the work on multiple antibiotic classes. This expertise has allowed us to identify and build a portfolio of product candidates for the treatment of infections due to MDR gram-negative pathogens.